Article

Microplasmin receives orphan drug protection

Dublin-The FDA has classified a new microplasmin compound for use in pediatric vitrectomy as an orphan drug.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
(Image credit: Ophthalmology Times) CCOI Myopia Workshop: Michael X. Repka, MD, MBA, on building consensus and future directions
Related Content
(Image credit: AdobeStock/racesy) Q&A: Inside the CCOI Myopia Workshop with Assoc Prof Daniel Ting
September 13th 2025

Q&A: Inside the CCOI Myopia Workshop with Assoc Prof Daniel Ting

ROP: Treating and preventing blindness in preterm babies
September 13th 2025

ROP: Treating and preventing blindness in preterm babies

Study data show parental delay is biggest factor in late retinoblastoma diagnosis
September 13th 2025

Study data show parental delay is biggest factor in late retinoblastoma diagnosis

Managing a changing landscape of IRD pediatric cases
September 13th 2025

Managing a changing landscape of IRD pediatric cases

Japanese researchers link outdoor time to rapid increase in choroidal thickness
September 13th 2025

Japanese researchers link outdoor time to rapid increase in choroidal thickness

(Image credit: AdobeStock/Bonsales) Q&A: Natalie Afshari, MD, FACS, on-label pediatric IOLs: turning advocacy into access
September 13th 2025

Q&A: Natalie Afshari, MD, FACS, championing on-label pediatric IOLs: turning advocacy into access

© 2025 MJH Life Sciences

All rights reserved.